Table 2 Therapeutics on last follow-up
From: Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation
Insulin | T1DM (n = 44) | LADA (n = 46) | p |
|---|---|---|---|
No insulin, n (%) | 0 (0%) | 4 (8.7%) | 0.117 |
Basal insulin, n (%) | 3 (6.8%) | 5 (10.9%) | 0.714 |
Premixed insulin, n (%) | 6 (13.6%) | 5 (10.9%) | 0.689 |
Basal-plus, n (%) | 1 (2.3%) | 4 (8.7%) | 0.361 |
Basal-bolus (MDI), n (%) | 32 (72.7%) | 27 (58.6%) | 0.161 |
CSII, n (%) | 2 (4.6%) | 1 (2.2%) | 0.612 |
Total daily dose (IU), median (IQR) | 40.0 (32.0) | 33.5 (33.0) | 0.819 |
Total daily dose (IU)/Weight (kg), mean (± SD) | 0.58 (± 0.31) | 0.57 (± 0.39) | 0.887 |
Non-insulin drugs | |||
Total, n (%) | 9 (20.5%) | 25 (54.3%) | 0.001* |
Metformin, n (%) | 7 (15.9%) | 22 (47.8%) | 0.001* |
Sulfonylureas, n (%) | 0 (0%) | 1 (2.2%) | 1.000 |
DPP4-i, n (%) | 5 (11.4%) | 17 (37.0%) | 0.005* |
GLP1-ra, n (%) | 0 (0%) | 1 (2.2%) | 1.000 |
SGLT2-i, n (%) | 0 (0%) | 2 (4.3%) | 0.495 |